BioNTech SE (BioNTech SE) Gross Profit : $3,470 Mil (TTM As of Dec. 2023)

View and export this data going back to 2019. Start your Free Trial

What is BioNTech SE Gross Profit?

BioNTech SE's gross profit for the three months ended in Dec. 2023 was $1,418 Mil. BioNTech SE's gross profit for the trailing twelve months (TTM) ended in Dec. 2023 was $3,470 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. BioNTech SE's gross profit for the three months ended in Dec. 2023 was $1,418 Mil. BioNTech SE's Revenue for the three months ended in Dec. 2023 was $1,613 Mil. Therefore, BioNTech SE's Gross Margin % for the quarter that ended in Dec. 2023 was 87.89%.

BioNTech SE had a gross margin of 87.89% for the quarter that ended in Dec. 2023 => Durable competitive advantage

During the past 8 years, the highest Gross Margin % of BioNTech SE was 89.27%. The lowest was 82.70%. And the median was 84.66%.

Warning Sign:

BioNTech SE gross margin has been in long-term decline. The average rate of decline per year is -1.1%.

BioNTech SE Gross Profit Historical Data

The historical data trend for BioNTech SE's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioNTech SE Gross Profit Chart

BioNTech SE Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Gross Profit

Get a 7-Day Free Trial

101.33

514.60

18,152.77

15,164.83

3,510.58

BioNTech SE Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Gross Profit	Get a 7-Day Free Trial															4,337.71	1,264.45	5.20	782.82	1,417.56

Competitive Comparison of BioNTech SE's Gross Profit

For the Biotechnology subindustry, BioNTech SE's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BioNTech SE's Gross Profit Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioNTech SE's Gross Profit distribution charts can be found below:

* The bar in red indicates where BioNTech SE's Gross Profit falls into.

BioNTech SE Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

BioNTech SE's Gross Profit for the fiscal year that ended in Dec. 2023 is calculated as

Gross Profit (A: Dec. 2023 )	=	Revenue	-	Cost of Goods Sold
	=	4164.667	-	654.089
	=	3,511

BioNTech SE's Gross Profit for the quarter that ended in Dec. 2023 is calculated as

Gross Profit (Q: Dec. 2023 )	=	Revenue	-	Cost of Goods Sold
	=	1612.868	-	195.311
	=	1,418

Gross Profit for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $3,470 Mil.

Gross Profit is the numerator in the calculation of Gross Margin.

BioNTech SE's Gross Margin % for the quarter that ended in Dec. 2023 is calculated as

Gross Margin % (Q: Dec. 2023 )	=	Gross Profit (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	(Revenue - Cost of Goods Sold)	/	Revenue
	=	1,418	/	1612.868
	=	87.89 %

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.

BioNTech SE (NAS:BNTX) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

BioNTech SE had a gross margin of 87.89% for the quarter that ended in Dec. 2023 => Durable competitive advantage

BioNTech SE Gross Profit Related Terms

Thank you for viewing the detailed overview of BioNTech SE's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.

BioNTech SE (BioNTech SE) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioNTech SE (NAS:BNTX) » Definitions » Gross Profit

Comparable Companies

Traded in Other Exchanges

BNTX:Mexico 0A3M:UK 22UA:Germany B1NT34:Brazil BNTX:Austria

Address

An der Goldgrube 12, Mainz, RP, DEU, D-55131

Website

https://www.biontech.de

BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and small-molecule immunomodulators. BioNTech is partnered with several large pharmaceutical companies, including Roche, Eli Lilly, Pfizer, Sanofi, and Genmab. COVID-19 vaccine Comirnaty is its first commercialized product.